

Patient	Age	Sex	PS	Histology Subtype	Category Risk	Everolimus Posology (mg)	Mean Everolimus Blood Concentration (µg/L)	Response	PFS (months)	OS (months)	Immune group
#1	52	M	1	CCRCC	High	5	53.7 (40-79)	SD	5.57	28.70	NA
#2	67	M	1	CCRCC	Int	10	15 (8.4-18)	SD	27.57	33.17	3
#3	83	M	2	CCRCC	High	5	8.8 (6-8.8)	PD	3.10	8.00	2
#4	51	M	1	CCRCC	High	10	20.4 (17.4-26.5)	SD	4.87	15.70	1
#5	83	M	2	CCRCC	Int	10	8 (7.6-10.2)	SD	8.00	15.80	2
#6	56	F	1	CCRCC	High	10	7.5 (7.5-10.5)	PD	4.13	15.30	1
#7	65	M	0	CCRCC	Low	10	15.6 (9.4-21.7)	SD	13.27	35.60	3
#8	80	M	1	CCRCC	Low	5	11.2 (7.4-23.6)	PR	6.47	7.57	2
#9	80	F	1	CCRCC	Int	5	3.9 (3.6-4.2)	SD	12.83	15.43	3
#10	63	F	1	CCRCC	High	10	15.6 (13.4-17.2)	PR	3.03	5.23	NA
#11	59	M	2	CCRCC	Int	5	7.4 (4.7-8.3)	SD	19.03	18.90	2
#12	65	M	2	CCRCC	High	10	6.8 (3.5-10.8)	SD	7.53	10.03	2
#13	71	M	0	CCRCC	High	5	28.7 (25.6-39)	PD	3.27	22.60	1
#14	67	M	1	CCRCC	Int	5	28.8 (18.8-38.9)	SD	5.93	12.03	1
#15	66	M	1	CCRCC	Low	5	6.6 (3.8-13.5)	SD	32.67	32.87	3
#16	67	M	1	CCRCC	Int	5	8.4 (7.7-15.5)	SD	13.13	35.73	2
#17	81	F	2	CCRCC	Int	5	6.2 (5.5-7)	SD	8.37	5.43	2
#18	80	M	1	papillary renal carcinoma	Low	5	10.4 (4.7-18)	PR	17.80	18.50	2
#19	66	M	1	CCRCC	High	5	20.3 (13.4-20.7)	SD	8.87	9.53	1
#20	72	M	1	CCRCC	Int	10	14.7 (7.5-15.3)	PD	3.53	15.07	2
#21	82	M	1	CCRCC	Low	10	12.2 (3.7-12.8)	PD	4.00	5.20	1
#22	66	M	1	CCRCC	Low	5	4 (3.8-4.3)	SD	10.97	10.97	2
#23	74	M	2	papillary renal carcinoma	High	10	13.4 (9.7-18.8)	SD	6.37	6.37	2

Supplementary Table S1. Patients' characteristics.

Category risk of renal carcinoma was assessed with Heng *et al.* category risk classification (20). Response indicates the best response during everolimus treatment. The immune groups 1, 2 and 3 were described in supplementary materials and methods section. CCRCC indicates clear cell renal cell carcinoma, SD stable disease, PR partial response, PS *performans status*, PD progression disease, PFS Progression Free Survival, OS Overall Survival.